The talk at the GRx+Biosims 2018 meeting this month in Baltimore was about challenges, but extrapolation was not one of them. Biosimilar interchangeability was. That was not entirely surprising. In market research projects I’ve been involved with over the past year, payers and physicians in medical groups have broadly indicated that they’ve gotten past the … Continue reading More From GRx+Biosims on Four-Letter Suffixes and Biosimilar Interchangeability
Tag: Biosimilar Council
Lessons From a New Report: Do More Biosimilar Approvals Necessarily Mean Greater Access to Biologics?
Avalere Health issued a new report indicating that by 2025, 1.2 million US patients will be able to access biologic therapy because of biosimilar approvals. Why does biosimilar approval mean better access?
Biosimilar Industry Group Urges Congress to Address Part B Reimbursement
Reimbursement of biosimilars for Medicare Part B beneficiaries has long been an issue for biosimilar manufacturers.
